{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:43:02Z","timestamp":1792788182121,"version":"4.5.0"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T00:00:00Z","timestamp":1789776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T00:00:00Z","timestamp":1790035200000},"content-version":"vor","delay-in-days":3,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Universit\u00e4tsklinikum T\u00fcbingen","id":[{"id":"https:\/\/ror.org\/00pjgxh97","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Transl Med"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Melanoma remains a highly aggressive malignancy, and many patients fail to achieve durable benefit despite immune checkpoint inhibitor (ICI) therapy. ICIs improve outcomes but lack tumor specificity and do not directly recruit T-cells to tumor cells resulting in substantial side effects, highlighting the need for targeted immunotherapies selectively toward melanoma. Neuron glial antigen-2 (NG2) represents an attractive antigen for T-cell redirecting strategies due to its largely tumor restricted expression.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Here we report the generation and characterization of T-cell engaging NG2\u2011targeting bispecific antibodies. (bsAbs). To finetune CD3 affinity, we generated two constructs with differing CD3-affinities. NG2xCD3\n                      <jats:italic>high<\/jats:italic>\n                      contains a UCHT-1-based CD3-binder with high affinity, whereas NG2xCD3\n                      <jats:italic>low<\/jats:italic>\n                      carries a UCHT\u20111 variant with approximately 100\u2011fold reduced CD3 affinity. Both constructs were functionally assessed in NG2-high and NG2-low melanoma cell lines covering several key aspects of T-cell mediated immune response.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      In cultures with NG2-expressing melanoma cells, both constructs mediated immune-synapse formation, T-cell activation, proliferation, and strictly NG2-dependent tumor cell killing. Both NG2xCD3\n                      <jats:italic>high<\/jats:italic>\n                      and NG2xCD3\n                      <jats:italic>low<\/jats:italic>\n                      supported differentiation into memory T\u2011cell subsets, but NG2xCD3\n                      <jats:italic>low<\/jats:italic>\n                      induced less cytokine secretion and diminished functional activity, particularly against NG2 lower expressing targets. NG2xCD3\n                      <jats:italic>high<\/jats:italic>\n                      maintained robust cytokine production and sustained cytotoxicity across both NG2\u2011high and NG2\u2011low tumor models.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>\n                      Our data identify NG2 as a promising target for T-cell-redirecting therapy in melanoma and demonstrate that, within the IgG-scFv format, high CD3 affinity is required to achieve potent effector function across differing NG2-expression levels. NG2xCD3\n                      <jats:italic>high<\/jats:italic>\n                      was thus identified as lead candidate for further development in NG2-expressing malignancies.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12967-026-09000-5","type":"journal-article","created":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T10:04:18Z","timestamp":1789812258000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Generation of an NG2 targeting bispecific antibody for the induction of T-cell immunity against melanoma"],"prefix":"10.1186","volume":"24","author":[{"given":"Nisha","family":"Prakash","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian","family":"H\u00f6rner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilona","family":"Hagelstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josephine","family":"Keller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gundram","family":"Jung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helmut R.","family":"Salih","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2576-2442","authenticated-orcid":false,"given":"Martina S.","family":"Lutz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,19]]},"reference":[{"key":"9000_CR1","doi-asserted-by":"crossref","unstructured":"Kuras M. Exploring the complex and multifaceted interplay between melanoma cells and the tumor microenvironment. Int J Mol Sci. 2023;24(18).","DOI":"10.3390\/ijms241814403"},{"issue":"1","key":"9000_CR2","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1111\/pcmr.12172","volume":"27","author":"RR Braeuer","year":"2014","unstructured":"Braeuer RR, Watson IR, Wu CJ, Mobley AK, Kamiya T, Shoshan E, et al. Why is melanoma so metastatic? Pigment Cell Melanoma Res. 2014;27(1):19\u201336.","journal-title":"Pigment Cell Melanoma Res"},{"issue":"5","key":"9000_CR3","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1002\/path.5213","volume":"247","author":"R Rabbie","year":"2019","unstructured":"Rabbie R, Ferguson P, Molina-Aguilar C, Adams DJ, Robles-Espinoza CD. Melanoma subtypes: genomic profiles, prognostic molecular markers and therapeutic possibilities. J Pathol. 2019;247(5):539\u201351.","journal-title":"J Pathol"},{"key":"9000_CR4","doi-asserted-by":"publisher","first-page":"702287","DOI":"10.3389\/fonc.2021.702287","volume":"11","author":"Y Ma","year":"2021","unstructured":"Ma Y, Xia R, Ma X, Judson-Torres RL, Zeng H. Mucosal Melanoma: Pathological Evolution, Pathway Dependency and Targeted Therapy. Front Oncol. 2021;11:702287.","journal-title":"Front Oncol"},{"issue":"5","key":"9000_CR5","doi-asserted-by":"publisher","first-page":"e70051","DOI":"10.1111\/pcmr.70051","volume":"38","author":"J Nowowiejska","year":"2025","unstructured":"Nowowiejska J, Ordon AJ, Purpurowicz P, Argenziano G, Piccolo V. Many Faces of Melanoma: A Comparison Between Cutaneous, Mucosal, Acral, Nail, and Ocular Malignancy. Pigment Cell Melanoma Res. 2025;38(5):e70051.","journal-title":"Pigment Cell Melanoma Res"},{"issue":"10400","key":"9000_CR6","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1016\/S0140-6736(23)00821-8","volume":"402","author":"GV Long","year":"2023","unstructured":"Long GV, Swetter SM, Menzies AM, Gershenwald JE, Scolyer RA. Cutaneous melanoma. Lancet. 2023;402(10400):485\u2013502.","journal-title":"Lancet"},{"key":"9000_CR7","doi-asserted-by":"crossref","unstructured":"Lopes J, Rodrigues CMP, Gaspar MM, Reis CP. Melanoma management: from epidemiology to treatment and latest advances. Cancers (Basel). 2022;14(19).","DOI":"10.3390\/cancers14194652"},{"issue":"5","key":"9000_CR8","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1001\/jamadermatol.2022.0160","volume":"158","author":"F Bray","year":"2022","unstructured":"Bray F, Vaccarella S, de Vries E, Arnold M, Singh D, Meheus F, et al. Global Burden of Cutaneous Melanoma in 2020 and Projections to 2040. JAMA Dermatology. 2022;158(5):495\u2013503.","journal-title":"JAMA Dermatology"},{"key":"9000_CR9","first-page":"212242","volume":"2012","author":"TR Velho","year":"2012","unstructured":"Velho TR. Metastatic melanoma - a review of current and future drugs. Drugs Context. 2012;2012:212242.","journal-title":"Drugs Context"},{"issue":"1","key":"9000_CR10","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1186\/s12967-025-06093-2","volume":"23","author":"Q Hu","year":"2025","unstructured":"Hu Q, Xuan J, Wang L, Shen K, Gao Z, Zhou Y, et al. Application of adoptive cell therapy in malignant melanoma. J Transl Med. 2025;23(1):102.","journal-title":"J Transl Med"},{"issue":"3","key":"9000_CR11","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1001\/jamaoncol.2015.0565","volume":"1","author":"DB Johnson","year":"2015","unstructured":"Johnson DB, Sosman JA. Therapeutic Advances and Treatment Options in Metastatic Melanoma. JAMA Oncol. 2015;1(3):380\u20136.","journal-title":"JAMA Oncol"},{"issue":"8","key":"9000_CR12","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1038\/nrclinonc.2017.43","volume":"14","author":"JJ Luke","year":"2017","unstructured":"Luke JJ, Flaherty KT, Ribas A, Long GV. Targeted agents and immunotherapies: optimizing outcomes in melanoma. Nat Reviews Clin Oncol. 2017;14(8):463\u201382.","journal-title":"Nat Reviews Clin Oncol"},{"key":"9000_CR13","doi-asserted-by":"crossref","unstructured":"Natarelli N, Aleman SJ, Mark IM, Tran JT, Kwak S, Botto E, et al. A review of current and pipeline drugs for treatment of melanoma. Pharmaceuticals (Basel). 2024;17(2).","DOI":"10.3390\/ph17020214"},{"key":"9000_CR14","doi-asserted-by":"publisher","first-page":"1403021","DOI":"10.3389\/fmolb.2024.1403021","volume":"11","author":"C Sorino","year":"2024","unstructured":"Sorino C, Iezzi S, Ciuffreda L, Falcone I. Immunotherapy in melanoma: advances, pitfalls, and future perspectives. Front Mol Biosci. 2024;11:1403021.","journal-title":"Front Mol Biosci"},{"issue":"6","key":"9000_CR15","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.1158\/1078-0432.CCR-17-2267","volume":"24","author":"TN Gide","year":"2018","unstructured":"Gide TN, Wilmott JS, Scolyer RA, Long GV. Primary and Acquired Resistance to Immune Checkpoint Inhibitors in Metastatic Melanoma. Clin Cancer Res. 2018;24(6):1260\u201370.","journal-title":"Clin Cancer Res"},{"issue":"7","key":"9000_CR16","doi-asserted-by":"publisher","first-page":"e23062","DOI":"10.1371\/journal.pone.0023062","volume":"6","author":"J Wang","year":"2011","unstructured":"Wang J, Svendsen A, Kmiecik J, Immervoll H, Skaftnesmo KO, Planaguma J, et al. Targeting the NG2\/CSPG4 proteoglycan retards tumour growth and angiogenesis in preclinical models of GBM and melanoma. PLoS ONE. 2011;6(7):e23062.","journal-title":"PLoS ONE"},{"issue":"3","key":"9000_CR17","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1002\/ijc.2910280307","volume":"28","author":"BS Wilson","year":"1981","unstructured":"Wilson BS, Imai K, Natali PG, Ferrone S. Distribution and molecular characterization of a cell-surface and a cytoplasmic antigen detectable in human melanoma cells with monoclonal antibodies. Int J Cancer. 1981;28(3):293\u2013300.","journal-title":"Int J Cancer"},{"key":"9000_CR18","doi-asserted-by":"crossref","unstructured":"Campoli M, Ferrone S, Wang X. Chapter 3 - functional and clinical relevance of chondroitin sulfate proteoglycan 4. In: Vande Woude GF, Klein G, editors. Adv Canc Res. Academic Press. 2010;109:73\u2013121.","DOI":"10.1016\/B978-0-12-380890-5.00003-X"},{"issue":"6","key":"9000_CR19","doi-asserted-by":"publisher","first-page":"1148","DOI":"10.1111\/j.1755-148X.2011.00929.x","volume":"24","author":"MA Price","year":"2011","unstructured":"Price MA, Colvin Wanshura LE, Yang J, Carlson J, Xiang B, Li G, et al. CSPG4, a potential therapeutic target, facilitates malignant progression of melanoma. Pigment Cell Melanoma Res. 2011;24(6):1148\u201357.","journal-title":"Pigment Cell Melanoma Res"},{"key":"9000_CR20","doi-asserted-by":"crossref","unstructured":"Zhang H, Wu Z, Hu D, Yan M, Sun J, Lai J, et al. Immunotherapeutic targeting of NG2\/CSPG4 in solid organ cancers. Vaccines (Basel). 2022;10(7).","DOI":"10.3390\/vaccines10071023"},{"key":"9000_CR21","doi-asserted-by":"publisher","first-page":"19","DOI":"10.3390\/cancers16193260","volume":"16","author":"X Chen","year":"2024","unstructured":"Chen X, Habib S, Alexandru M, Chauhan J, Evan T, Troka JM, et al. Chondroitin Sulfate Proteoglycan 4 (CSPG4) as an Emerging Target for Immunotherapy to Treat Melanoma. Cancers (Basel). 2024;16:19.","journal-title":"Cancers (Basel)"},{"key":"9000_CR22","doi-asserted-by":"crossref","unstructured":"Torisu-Itakura H, Schoellhammer HF, Sim MS, Irie RF, Hausmann S, Raum T, et al. Redirected lysis of human melanoma cells by a MCSP\/CD3-bispecific BiTE antibody that engages patient-derived T cells. J Immunother. 2011;34(8).","DOI":"10.1097\/CJI.0b013e3182307fd8"},{"issue":"22","key":"9000_CR23","doi-asserted-by":"publisher","first-page":"1665","DOI":"10.1038\/s41388-025-03332-0","volume":"44","author":"D Greiner","year":"2025","unstructured":"Greiner D, Xue Q, Waddell TQ, Kurudza E, Chaudhary P, Belote RL, et al. Human CSPG4-targeting CAR-macrophages inhibit melanoma growth. Oncogene. 2025;44(22):1665\u201377.","journal-title":"Oncogene"},{"key":"9000_CR24","doi-asserted-by":"publisher","first-page":"1911","DOI":"10.3389\/fimmu.2017.01911","volume":"8","author":"KM Ilieva","year":"2017","unstructured":"Ilieva KM, Cheung A, Mele S, Chiaruttini G, Crescioli S, Griffin M, et al. Chondroitin Sulfate Proteoglycan 4 and Its Potential As an Antibody Immunotherapy Target across Different Tumor Types. Front Immunol. 2017;8:1911.","journal-title":"Front Immunol"},{"key":"9000_CR25","doi-asserted-by":"crossref","unstructured":"Mehta NK, Pfluegler M, Meetze K, Li B, Sindel I, Vogt F, et al. A novel IgG-based FLT3xCD3 bispecific antibody for the treatment of AML and B-ALL. J Immunother Cancer. 2022;10(3).","DOI":"10.1136\/jitc-2021-003882"},{"issue":"2","key":"9000_CR26","doi-asserted-by":"publisher","first-page":"e11902","DOI":"10.15252\/emmm.201911902","volume":"13","author":"L Zekri","year":"2021","unstructured":"Zekri L, Vogt F, Osburg L, Muller S, Kauer J, Manz T, et al. An IgG-based bispecific antibody for improved dual targeting in PSMA-positive cancer. EMBO Mol Med. 2021;13(2):e11902.","journal-title":"EMBO Mol Med"},{"issue":"4","key":"9000_CR27","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1016\/j.ymthe.2023.02.010","volume":"31","author":"L Zekri","year":"2023","unstructured":"Zekri L, Lutz M, Prakash N, Manz T, Klimovich B, Mueller S, et al. An optimized IgG-based B7-H3xCD3 bispecific antibody for treatment of gastrointestinal cancers. Mol Ther. 2023;31(4):1033\u201345.","journal-title":"Mol Ther"},{"issue":"10","key":"9000_CR28","doi-asserted-by":"publisher","first-page":"e039639","DOI":"10.1136\/bmjopen-2020-039639","volume":"10","author":"JS Heitmann","year":"2020","unstructured":"Heitmann JS, Walz JS, Pflugler M, Kauer J, Schlenk RF, Jung G, et al. Protocol of a prospective, multicentre phase I study to evaluate the safety, tolerability and preliminary efficacy of the bispecific PSMAxCD3 antibody CC-1 in patients with castration-resistant prostate carcinoma. BMJ Open. 2020;10(10):e039639.","journal-title":"BMJ Open"},{"key":"9000_CR29","doi-asserted-by":"publisher","first-page":"1351901","DOI":"10.3389\/fonc.2024.1351901","volume":"14","author":"S Jung","year":"2024","unstructured":"Jung S, Schlenk RF, Hackenbruch C, Roldan Pinzon SSL, Bitzer M, Pflugler M, et al. Protocol of a first-in-human clinical trial to evaluate the safety, tolerability, and preliminary efficacy of the bispecific CD276xCD3 antibody CC-3 in patients with colorectal cancer (CoRe_CC-3). Front Oncol. 2024;14:1351901.","journal-title":"Front Oncol"},{"key":"9000_CR30","doi-asserted-by":"publisher","first-page":"1163136","DOI":"10.3389\/fimmu.2023.1163136","volume":"14","author":"MS Lutz","year":"2023","unstructured":"Lutz MS, Zekri L, Wessling L, Berchtold S, Heitmann JS, Lauer UM, et al. IgG-based B7-H3xCD3 bispecific antibody for treatment of pancreatic, hepatic and gastric cancer. Front Immunol. 2023;14:1163136.","journal-title":"Front Immunol"},{"issue":"1","key":"9000_CR31","doi-asserted-by":"publisher","first-page":"902","DOI":"10.1186\/s12967-024-05689-4","volume":"22","author":"I Hagelstein","year":"2024","unstructured":"Hagelstein I, Wessling L, Rochwarger A, Zekri L, Klimovich B, Tegeler CM, et al. Targeting CD276 for T cell-based immunotherapy of breast cancer. J Transl Med. 2024;22(1):902.","journal-title":"J Transl Med"},{"key":"9000_CR32","doi-asserted-by":"publisher","first-page":"1343929","DOI":"10.3389\/fimmu.2024.1343929","volume":"15","author":"MS Lutz","year":"2024","unstructured":"Lutz MS, Wang K, Jung G, Salih HR, Hagelstein I. An Fc-modified monoclonal antibody as novel treatment option for pancreatic cancer. Front Immunol. 2024;15:1343929.","journal-title":"Front Immunol"},{"issue":"1","key":"9000_CR33","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1186\/1472-6750-13-55","volume":"13","author":"SH Gao","year":"2013","unstructured":"Gao SH, Huang K, Tu H, Adler AS. Monoclonal antibody humanness score and its applications. BMC Biotechnol. 2013;13(1):55.","journal-title":"BMC Biotechnol"},{"issue":"24","key":"9000_CR34","doi-asserted-by":"publisher","first-page":"e71432","DOI":"10.1002\/cam4.71432","volume":"14","author":"R ElBeblawy","year":"2025","unstructured":"ElBeblawy R, Jani C, Perez-Granado J, Gramling M, Desai A. The Landscape of Bispecific Antibodies in Solid Tumor Oncology: Trends, Challenges, and Opportunities. Cancer Med. 2025;14(24):e71432.","journal-title":"Cancer Med"},{"issue":"16","key":"9000_CR35","doi-asserted-by":"publisher","first-page":"2893","DOI":"10.1200\/JCO.22.02823","volume":"41","author":"L Paz-Ares","year":"2023","unstructured":"Paz-Ares L, Champiat S, Lai WV, Izumi H, Govindan R, Boyer M, et al. Tarlatamab, a First-in-Class DLL3-Targeted Bispecific T-Cell Engager, in Recurrent Small-Cell Lung Cancer: An Open-Label, Phase I Study. J Clin Oncol. 2023;41(16):2893\u2013903.","journal-title":"J Clin Oncol"},{"key":"9000_CR36","doi-asserted-by":"crossref","unstructured":"Wang J, Sajeev G, Chai X, Takundwa R, Dirnberger F, Pundole X, et al. Efficacy outcomes between tarlatamab and real-world physicians\u2019 choice of therapies for previously treated extensive stage small cell lung cancer. Oncologist. 2025;30(9).","DOI":"10.1093\/oncolo\/oyaf256"},{"key":"9000_CR37","doi-asserted-by":"crossref","unstructured":"Shanshal M, Caimi PF, Adjei AA, Ma WW. T-cell engagers in solid cancers-current landscape and future directions. Cancers (Basel). 2023;15(10).","DOI":"10.3390\/cancers15102824"},{"issue":"1","key":"9000_CR38","doi-asserted-by":"publisher","first-page":"2531223","DOI":"10.1080\/19420862.2025.2531223","volume":"17","author":"C Bergamaschi","year":"2025","unstructured":"Bergamaschi C, Gaspar M, Ciucci T, Sitnikova SI, Cayatte C, Pica M, et al. Innovative strategies for T cell engagers for cancer immunotherapy. MAbs. 2025;17(1):2531223.","journal-title":"MAbs"},{"key":"9000_CR39","doi-asserted-by":"crossref","unstructured":"Abdelmotaleb O, Schneider A, Waldhauer I, Sam J, Hofer T, Lechmann M, et al. Optimizing efficacy and safety of T cell bispecific antibodies: the interdependence of CD3 and tumor antigen binder affinities in FOLR1 and CEACAM5 2\u2009+\u20091 TCBs. mAbs. 2025;17(1).","DOI":"10.1080\/19420862.2025.2584374"},{"issue":"1","key":"9000_CR40","doi-asserted-by":"publisher","first-page":"14397","DOI":"10.1038\/s41598-021-93842-0","volume":"11","author":"L Haber","year":"2021","unstructured":"Haber L, Olson K, Kelly MP, Crawford A, DiLillo DJ, Tavare R, et al. Generation of T-cell-redirecting bispecific antibodies with differentiated profiles of cytokine release and biodistribution by CD3 affinity tuning. Sci Rep. 2021;11(1):14397.","journal-title":"Sci Rep"},{"issue":"10","key":"9000_CR41","doi-asserted-by":"publisher","first-page":"1600","DOI":"10.1158\/1535-7163.MCT-24-0846","volume":"24","author":"D Wu","year":"2025","unstructured":"Wu D, Huang L, Naren G, Zhang R, Gong S, Wu X, et al. Optimization of a Novel 2\u2009+\u20092 BCMA \u00d7 CD3 Bispecific Antibody for Minimized Cytokine Release and Potent Efficacy. Mol Cancer Ther. 2025;24(10):1600\u201310.","journal-title":"Mol Cancer Ther"},{"issue":"5","key":"9000_CR42","doi-asserted-by":"publisher","first-page":"530","DOI":"10.7150\/thno.10824","volume":"5","author":"PA Nicolosi","year":"2015","unstructured":"Nicolosi PA, Dallatomasina A, Perris R. Theranostic impact of NG2\/CSPG4 proteoglycan in cancer. Theranostics. 2015;5(5):530\u201344.","journal-title":"Theranostics"},{"issue":"8","key":"9000_CR43","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1007\/s00262-010-0844-y","volume":"59","author":"C Bluemel","year":"2010","unstructured":"Bluemel C, Hausmann S, Fluhr P, Sriskandarajah M, Stallcup WB, Baeuerle PA, et al. Epitope distance to the target cell membrane and antigen size determine the potency of T cell-mediated lysis by BiTE antibodies specific for a large melanoma surface antigen. Cancer Immunol Immunother. 2010;59(8):1197\u2013209.","journal-title":"Cancer Immunol Immunother"},{"issue":"3","key":"9000_CR44","doi-asserted-by":"publisher","first-page":"382","DOI":"10.3892\/ol.2023.13968","volume":"26","author":"A Grossauer","year":"2023","unstructured":"Grossauer A, Uranowska K, Kitzwogerer M, Mostegel M, Breiteneder H, Hafner C. Immunohistochemical detection of the chondroitin sulfate proteoglycan 4 protein in primary and metastatic melanoma. Oncol Lett. 2023;26(3):382.","journal-title":"Oncol Lett"},{"issue":"16suppl","key":"9000_CR45","first-page":"e21540","volume":"43","author":"V Espeli","year":"2025","unstructured":"Espeli V, Heinosalo T, Nepote A, Mangas C, Baggiolini A, Chrusciel M. Effect of treatment resistance on CSPG4\u2009+\u2009expression in metastatic melanoma across multiple treatment lines. J Clin Oncol. 2025;43(16suppl):e21540\u2013e.","journal-title":"J Clin Oncol"},{"issue":"6","key":"9000_CR46","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1038\/s43018-025-00963-w","volume":"6","author":"S Guetter","year":"2025","unstructured":"Guetter S, Konig C, Koerkel-Qu H, Markiewicz A, Scheitler S, Katzer M, et al. MCSP(+) metastasis founder cells activate immunosuppression early in human melanoma metastatic colonization. Nat Cancer. 2025;6(6):1017\u201334.","journal-title":"Nat Cancer"},{"issue":"2","key":"9000_CR47","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1080\/19420862.2016.1268307","volume":"9","author":"U Brinkmann","year":"2017","unstructured":"Brinkmann U, Kontermann RE. The making of bispecific antibodies. MAbs. 2017;9(2):182\u2013212.","journal-title":"MAbs"},{"key":"9000_CR48","doi-asserted-by":"publisher","first-page":"1667210","DOI":"10.3389\/fphar.2025.1667210","volume":"16","author":"NG Metzendorf","year":"2025","unstructured":"Metzendorf NG, Petersen I, Hultqvist G. Enhancing therapeutic antibody profiling: orthogonal strategies for stability and quality assessment. Front Pharmacol. 2025;16:1667210.","journal-title":"Front Pharmacol"},{"issue":"1","key":"9000_CR49","doi-asserted-by":"publisher","first-page":"2394229","DOI":"10.1080\/19420862.2024.2394229","volume":"16","author":"A Amash","year":"2024","unstructured":"Amash A, Volkers G, Farber P, Griffin D, Davison KS, Goodman A, et al. Developability considerations for bispecific and multispecific antibodies. MAbs. 2024;16(1):2394229.","journal-title":"MAbs"},{"issue":"5","key":"9000_CR50","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1053\/j.seminoncol.2014.08.004","volume":"41","author":"UH Weidle","year":"2014","unstructured":"Weidle UH, Kontermann RE, Brinkmann U. Tumor-antigen-binding bispecific antibodies for cancer treatment. Semin Oncol. 2014;41(5):653\u201360.","journal-title":"Semin Oncol"},{"issue":"12","key":"9000_CR51","doi-asserted-by":"publisher","first-page":"2013","DOI":"10.1158\/2326-6066.CIR-19-0121","volume":"7","author":"L Wang","year":"2019","unstructured":"Wang L, Hoseini SS, Xu H, Ponomarev V, Cheung NK. Silencing Fc Domains in T cell-Engaging Bispecific Antibodies Improves T-cell Trafficking and Antitumor Potency. Cancer Immunol Res. 2019;7(12):2013\u201324.","journal-title":"Cancer Immunol Res"},{"issue":"4","key":"9000_CR52","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1080\/19420862.2019.1574521","volume":"11","author":"ND Trinklein","year":"2019","unstructured":"Trinklein ND, Pham D, Schellenberger U, Buelow B, Boudreau A, Choudhry P, et al. Efficient tumor killing and minimal cytokine release with novel T-cell agonist bispecific antibodies. mAbs. 2019;11(4):639\u201352.","journal-title":"mAbs"},{"issue":"6","key":"9000_CR53","doi-asserted-by":"publisher","first-page":"e002488","DOI":"10.1136\/jitc-2021-002488","volume":"9","author":"K Dang","year":"2021","unstructured":"Dang K, Castello G, Clarke SC, Li Y, Balasubramani A, Boudreau A, et al. Attenuating CD3 affinity in a PSMAxCD3 bispecific antibody enables killing of prostate tumor cells with reduced cytokine release. J Immunother Cancer. 2021;9(6):e002488.","journal-title":"J Immunother Cancer"},{"key":"9000_CR54","doi-asserted-by":"crossref","unstructured":"Shakiba M, Zumbo P, Espinosa-Carrasco G, Menocal L, Dundar F, Carson SE, et al. TCR signal strength defines distinct mechanisms of T cell dysfunction and cancer evasion. J Exp Med. 2022;219(2).","DOI":"10.1084\/jem.20201966"}],"container-title":["Journal of Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12967-026-09000-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-026-09000-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-026-09000-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T20:01:57Z","timestamp":1790107317000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12967-026-09000-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,19]]},"references-count":54,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["9000"],"URL":"https:\/\/doi.org\/10.1186\/s12967-026-09000-5","relation":{},"ISSN":["1479-5876"],"issn-type":[{"value":"1479-5876","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,19]]},"assertion":[{"value":"26 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study was approved by IRB (ethics committee of the Faculty of Medicine of the Eberhard Karls Universitaet Tuebingen) at the University Hospital Tuebingen and was conducted in accordance with the Declaration of Helsinki; reference number13\/2007 V. Human material was collected after obtaining informed consent.","order":1,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no potential conflicts of interest.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"1204"}}